A Phase III Study of Surgery with or without Hyperthermic Intraperitoneal Chemotherapy in People with Ovarian Cancer

Full Title

Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing between Primary Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy: OVHIPEC-2

Purpose

The purpose of this study is to see if adding hyperthermic intraperitoneal chemotherapy (HIPEC) to tumor removal surgery is more effective than the surgery alone in people with ovarian cancer that has spread beyond the ovaries. HIPEC involves giving a heated chemotherapy drug (cisplatin) directly into the belly at the end of the surgical procedure. It may help destroy any remaining cancer cells. Participants in this study will be randomly assigned to receive surgery with or without HIPEC.

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

• Participants must have ovarian cancer that has spread beyond the ovaries and will be surgically removed.
• Patients may not have previously received ovarian cancer treatment.
• This study is for people age 18 and older.

 

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Yukio Sonoda at 212-639-6450.